Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single-arm phase II toxicity-oriented trial.
Fiche publication
Date publication
août 2021
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RETIF Paul
Tous les auteurs :
Nguyen P, Harzée L, Retif P, Joseph S, Vogin G, Nickers P
Lien Pubmed
Résumé
There are no safety-focused trials on stereotactic body radiotherapy (SBRT) for localized prostate cancer. This prospective 3‑year phase II trial used binomial law to validate the safety and efficacy of SBRT with stringent organ at risk dose constraints that nevertheless permitted high planning target volume doses.
Mots clés
Binomial law, Cyberknife, Hypofractionation, Prostate cancer, Quality of life
Référence
Strahlenther Onkol. 2021 Aug 23;: